US11110093 — Sustained release small molecule drug formulation
Method of Use · Assigned to Indivior UK Ltd · Expires 2026-11-05 · 0y remaining
What this patent protects
This patent protects a sustained release injectable depot formulation that incorporates a small molecule drug, such as Risperdal, into a viscous gel.
USPTO Abstract
An injectable depot formulation includes a biocompatible polymer, an organic solvent combined with the biocompatible polymer to form a viscous gel, and a small molecule drug incorporated in the viscous gel such that the formulation exhibits an in vivo release profile having a C max to C min ratio of less than 200 and a lag time less than 0.2.
Drugs covered by this patent
- Risperdal (risperidone) · Johnson & Johnson (Janssen)
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-3135 |
— | Risperdal |
U-3135 |
— | Risperdal |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.